Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC decreased its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 4.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,578 shares of the company’s stock after selling 1,590 shares during the quarter. Mutual of America Capital Management LLC owned about 0.07% of Axsome Therapeutics worth $2,752,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. AQR Capital Management LLC increased its stake in Axsome Therapeutics by 1.7% during the 1st quarter. AQR Capital Management LLC now owns 8,825 shares of the company’s stock valued at $544,000 after purchasing an additional 148 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Axsome Therapeutics by 21.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 993 shares of the company’s stock valued at $71,000 after acquiring an additional 178 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Axsome Therapeutics by 1.1% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 18,734 shares of the company’s stock valued at $1,309,000 after acquiring an additional 197 shares during the last quarter. Fifth Third Bancorp boosted its holdings in shares of Axsome Therapeutics by 100.0% in the 3rd quarter. Fifth Third Bancorp now owns 400 shares of the company’s stock valued at $28,000 after acquiring an additional 200 shares during the last quarter. Finally, Rafferty Asset Management LLC boosted its holdings in shares of Axsome Therapeutics by 4.7% in the 3rd quarter. Rafferty Asset Management LLC now owns 4,560 shares of the company’s stock valued at $319,000 after acquiring an additional 205 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Wall Street Analysts Forecast Growth

AXSM has been the topic of several recent research reports. Piper Sandler upped their price objective on shares of Axsome Therapeutics from $90.00 to $113.00 and gave the company an “overweight” rating in a report on Tuesday, January 16th. Guggenheim upped their price objective on shares of Axsome Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday, February 21st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $107.00 price objective on shares of Axsome Therapeutics in a report on Wednesday, April 10th. Truist Financial reaffirmed a “buy” rating and issued a $150.00 price objective on shares of Axsome Therapeutics in a report on Tuesday, March 26th. Finally, HC Wainwright reissued a “buy” rating and set a $190.00 price target on shares of Axsome Therapeutics in a report on Tuesday, April 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, Axsome Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $119.67.

Axsome Therapeutics Stock Performance

AXSM opened at $65.72 on Friday. The company has a quick ratio of 3.52, a current ratio of 3.63 and a debt-to-equity ratio of 0.93. The company has a market cap of $3.11 billion, a price-to-earnings ratio of -12.64 and a beta of 1.13. Axsome Therapeutics, Inc. has a 52-week low of $55.02 and a 52-week high of $98.40. The firm’s fifty day simple moving average is $78.69 and its two-hundred day simple moving average is $75.10.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.21) by $0.48. The business had revenue of $71.53 million for the quarter, compared to the consensus estimate of $70.38 million. Axsome Therapeutics had a negative net margin of 88.41% and a negative return on equity of 70.67%. Equities analysts anticipate that Axsome Therapeutics, Inc. will post -3.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, Director Roger Jeffs sold 29,976 shares of the stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $69.70, for a total transaction of $2,089,327.20. Following the transaction, the director now directly owns 120,756 shares of the company’s stock, valued at $8,416,693.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, Director Roger Jeffs sold 29,976 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $69.70, for a total value of $2,089,327.20. Following the completion of the sale, the director now directly owns 120,756 shares in the company, valued at $8,416,693.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Mark L. Jacobson sold 24,662 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $77.24, for a total transaction of $1,904,892.88. The disclosure for this sale can be found here. Insiders own 24.50% of the company’s stock.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.